STOCK TITAN

Bionomics to Present at the ThinkEquity Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Bionomics (BNOX), a clinical-stage biotech company focused on developing allosteric ion channel modulators for CNS disorders, announces its participation in the ThinkEquity Conference on October 30, 2024. The event will be held at the Mandarin Oriental Hotel in New York. Dr. Spyros Papapetropoulos, President and CEO, will present at 1:30 p.m. ET in the Lotus Suite West. The presentation will be available via live webcast, and management will conduct one-on-one meetings with investors. A replay will be accessible on the company's website under the Events page.

Bionomics (BNOX), un'azienda biotech in fase clinica focalizzata sullo sviluppo di modulators ionici allosterici per disturbi del sistema nervoso centrale, annuncia la sua partecipazione alla ThinkEquity Conference che si terrà il 30 ottobre 2024. L'evento avrà luogo presso il Mandarin Oriental Hotel di New York. Il Dr. Spyros Papapetropoulos, Presidente e CEO, presenterà alle 13:30 ET nella Lotus Suite West. La presentazione sarà disponibile tramite webcast dal vivo, e il management condurrà incontri individuali con gli investitori. Una registrazione sarà accessibile sul sito web dell'azienda nella pagina Eventi.

Bionomics (BNOX), una empresa biotecnológica en fase clínica centrada en el desarrollo de moduladores de canales iónicos alostéricos para trastornos del sistema nervioso central, anuncia su participación en la ThinkEquity Conference el 30 de octubre de 2024. El evento se llevará a cabo en el Mandarin Oriental Hotel en Nueva York. El Dr. Spyros Papapetropoulos, Presidente y CEO, presentará a la 1:30 p.m. ET en la Lotus Suite West. La presentación estará disponible a través de un webcast en vivo, y la dirección llevará a cabo reuniones individuales con los inversores. Una repetición estará disponible en el sitio web de la empresa en la página de Eventos.

바이오노믹스 (BNOX), CNS 장애를 위한 알로스테릭 이온 채널 조절제를 개발하는 데 중점을 둔 임상 단계의 생명공학 회사, 오는 2024년 10월 30일 ThinkEquity Conference에 참석한다고 발표했습니다. 이 행사는 뉴욕의 만다린 오리엔탈 호텔에서 열립니다. 스파이로스 파파페트로풀로스 박사, 사장 겸 CEO가 동부 시간 기준 오후 1시 30분에 로터스 스위트 웨스트에서 발표를 합니다. 발표는 실시간 웹캐스트를 통해 제공되며, 경영진은 투자자와의 일대일 회의를 진행할 것입니다. 재생은 회사 웹사이트의 이벤트 페이지에서 접근 가능합니다.

Bionomics (BNOX), une entreprise biopharmaceutique en phase clinique axée sur le développement de modulateurs canaux ioniques allostériques pour les troubles du système nerveux central, annonce sa participation à la ThinkEquity Conference le 30 octobre 2024. L'événement se déroulera à l'hôtel Mandarin Oriental de New York. Dr. Spyros Papapetropoulos, Président et CEO, présentera à 13h30 ET dans la Lotus Suite West. La présentation sera disponible en direct via un webcast, et la direction organisera des réunions individuelles avec les investisseurs. Un enregistrement sera accessible sur le site internet de l'entreprise, sous la page Événements.

Bionomics (BNOX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allosterischen Ionenkanalmodulatoren für ZNS-Erkrankungen konzentriert, kündigt seine Teilnahme an der ThinkEquity Conference am 30. Oktober 2024 an. Die Veranstaltung findet im Mandarin Oriental Hotel in New York statt. Dr. Spyros Papapetropoulos, Präsident und CEO, wird um 13:30 Uhr ET in der Lotus Suite West präsentieren. Die Präsentation wird live über einen Webcast verfügbar sein, und die Geschäftsführung wird Einzelgespräche mit Investoren führen. Eine Wiederholung wird auf der Webseite des Unternehmens unter der Seite Veranstaltungen zugänglich sein.

Positive
  • None.
Negative
  • None.

ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating and presenting at the ThinkEquity Conference being held October 30, 2024 at the Mandarin Oriental Hotel in New York, NY.

Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will deliver a company presentation on October 30 at 1:30 p.m. ET in the Lotus Suite West. A live webcast of the presentation will be available here.

Company’s management will be available for one-on-one meetings during the conference. Interested investors should contact their ThinkEquity representative. A replay of the presentation will be posted, when available, to Bionomics’ website under the “Events” page of the Investors Center section.

FOR FURTHER INFORMATION PLEASE CONTACT:

General
Rajeev Chandra
Company Secretary
CoSec@bionomics.com.au
Investor Relations
Kevin Gardner
kgardner@lifesciadvisors.com

Investor Relations
Chris Calabrese
ccalabrese@lifesciadvisors.com
   

About Bionomics Limited
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other CNS conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au

Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the closing of each tranche of the Company’s private placement financing, the achievement of certain milestones for the various tranches, the timely funding to the Company by each investor in the private placement, the timing, size and expectation of the closing of the private placement; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the Company’s expectation that its current cash, cash equivalents, and marketable securities will fund our operations into the third quarter of 2025. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, the Company’s Annual Report on Form 20-F filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics’ filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Bionomics’ website (www.bionomics.com.au) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.


FAQ

When is Bionomics (BNOX) presenting at the ThinkEquity Conference 2024?

Bionomics (BNOX) will present on October 30, 2024, at 1:30 p.m. ET in the Lotus Suite West at the Mandarin Oriental Hotel in New York.

Where can investors watch Bionomics' (BNOX) ThinkEquity Conference presentation?

Investors can watch the presentation via live webcast, and a replay will be available on Bionomics' website under the Events page of the Investors Center section.

What type of meetings is Bionomics (BNOX) offering at the ThinkEquity Conference?

Bionomics' management team will be available for one-on-one meetings with investors during the conference. Interested investors should contact their ThinkEquity representative to schedule.

What is the main focus of Bionomics' (BNOX) drug development?

Bionomics focuses on developing novel, first-in-class, allosteric ion channel modulators to treat patients with serious central nervous system (CNS) disorders with high unmet medical need.

Bionomics Limited American Depository Shares

NASDAQ:BNOX

BNOX Rankings

BNOX Latest News

BNOX Stock Data

5.66M
12.91M
33.91%
16.22%
1.1%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EASTWOOD SA